Journal of Clinical Microbiology最新文献

{"title":"Performance evaluation of plazomicin susceptibility testing of Enterobacterales on VITEK 2 and VITEK 2 Compact Systems.","authors":"Edith Csiki-Fejer, Maria Traczewski, Gary W Procop, Thomas E Davis, Meredith Hackel, Gilles Zambardi","doi":"10.1128/jcm.00449-25","DOIUrl":"10.1128/jcm.00449-25","url":null,"abstract":"<p><p>The objective of the present study was to evaluate the VITEK 2 antimicrobial susceptibility test (AST) for Gram-negative (GN) plazomicin performance using the VITEK 2 and VITEK 2 Compact Systems in clinical settings and to demonstrate its equivalence to the Clinical and Laboratory Standards Institute (CLSI) broth microdilution (BMD) technique. The clinical study conducted at four external sites followed the requirements detailed in the US Food and Drug Administration (FDA) and International Standards Organization (ISO) guidance documents and included clinical, challenge, quality, and reproducibility studies. In this multisite study, a total of 979 Enterobacterales isolates were tested. The VITEK 2 card minimum inhibitory concentration (MIC) results were compared with the reference BMD MIC results. The performance following ISO criteria indicated Essential Agreement (EA) = 97.8% and showed that VITEK 2 plazomicin MIC results for Enterobacterales tend to be in exact agreement when compared with the CLSI BMD reference method, except for <i>Escherichia coli,</i> when MICs tend to be in exact agreement or at least one doubling dilution lower. The analysis was also performed following the FDA criteria using the breakpoints defined by the FDA: ≤2 susceptible (S), 4 intermediate (I), and ≥8 resistant (R) for Enterobacterales. The analysis showed the following performance: EA = 98.7%, category agreement (CA) = 99.4%, and major errors (ME) = 0.1%, with no very major errors (VME) present. There are three species, <i>Klebsiella pneumoniae</i>, <i>Escherichia coli,</i> and <i>Serratia marcescens,</i> for which the trend is ≥ 30% and therefore addressed as a note in the US label. The plazomicin test met the ISO and FDA criteria of ≥95% reproducibility and ≥95% quality control (QC) results within acceptable ranges for QC organisms.IMPORTANCEThe VITEK 2 AST-GN plazomicin test is a new, automated alternative to the BMD reference method for determining minimum inhibitory concentrations (MIC) of Enterobacterales, expanding the range of automatic AST testing.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0044925"},"PeriodicalIF":5.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144760210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All you need to know about equipment validation for sterility testing.","authors":"James E T Gebo, Kayla M Feehely, Chase E Lattimore, Dylan P Mogavero, Anna F Lau","doi":"10.1128/jcm.01477-24","DOIUrl":"10.1128/jcm.01477-24","url":null,"abstract":"<p><p>Product sterility testing requests are becoming increasingly common in clinical microbiology laboratories due to the rapid development of advanced therapies. Most laboratory directors are hesitant to bring on such tests because they fall under current Good Manufacturing Practices (cGMP) regulated by the United States Food and Drug Administration (FDA), where expectations differ from clinical requirements (regulated by the Centers for Medicare and Medicaid Services). When considerations are made for cGMP testing in the clinical lab, most focus is placed on analytical test validation. In this mini-review, we provide an overview of one critical element within the cGMP quality system-validation of equipment, software, and systems through installation, operational, and performance qualification (IQ, OQ, and PQ or IOPQ). This terminology is not common in clinical laboratories, and the IQ and OQ portions are often overlooked, not performed, and/or not documented, although phase II CAP requirements exist (COM.30550 and COM.30575). This mini-review will provide an overview of the IOPQ framework, what is included and how it differs from CAP requirements, important considerations for an IOPQ, and a summary of FDA citations relating to equipment validation. We provide examples using blood culture systems, controlled temperature units (CTUs; e.g., incubator), and the laboratory information management system, given their likelihood for use in cGMP activities in the clinical lab. Importantly, the IOPQ requirements summarized here would have also been relevant to laboratory-developed tests (LDTs) classified as \"devices\" prior to the March 31, 2025, annulment of the ruling.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0147724"},"PeriodicalIF":5.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144816828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Luciferase reporter mycobacteriophage (TM4::<i>GeNL</i>) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in <i>Mycobacterium abscessus</i> complex.","authors":"Saranathan Rajagopalan, Lahari Das, Donna J Kohlerschmidt, Amy K Rourke, Salika M Shakir, Michelle H Larsen, Max R O'Donnell, Wendy A Szymczak, Vincent E Escuyer, Phyu M Thwe, William R Jacobs","doi":"10.1128/jcm.00841-25","DOIUrl":"10.1128/jcm.00841-25","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;i&gt;Mycobacterium abscessus&lt;/i&gt; (MAB) infections are challenging to treat due to high-level resistance to anti-tuberculosis drugs, carbapenems, fluoroquinolones, and tetracyclines. Clarithromycin and amikacin are considered cornerstone drugs for MAB treatment due to their superior efficacy; however, assessing clarithromycin susceptibility typically takes 7 to 14 days because of inducible macrolide resistance. We developed a 48 h luciferase reporter mycobacteriophage drug susceptibility testing (LRM-DST) assay using TM4::&lt;i&gt;GeNL&lt;/i&gt; to evaluate MAB drug susceptibility. For this proof-of-principle study, we performed DST on 26 MAB clinical isolates using TM4::&lt;i&gt;GeNL&lt;/i&gt; and Sensititre RAPMYCO2 plates. Genome sequencing was performed to identify the MAB sub-species and for understanding intrinsic and acquired drug resistance mechanisms. We detected clarithromycin resistance in 12/26 (46%) by both Sensititre and LRM-DST. All clarithromycin-resistant isolates carried full-length inducible erythromycin ribosomal methylase-41 [&lt;i&gt;erm(41&lt;/i&gt;)] gene, and none had &lt;i&gt;rrl&lt;/i&gt; (23S rRNA) mutations. Amikacin resistance or intermediate amikacin resistance was detected in 6/26 (23%) isolates. Mutations in the &lt;i&gt;rrs&lt;/i&gt; (16S rRNA) gene at positions 1375A &gt; G (&lt;i&gt;E. coli&lt;/i&gt; 1408A &gt; G) conferred amikacin resistance in four isolates; however, no mutations were identified in two of the amikacin intermediate-resistant isolates. LRM-DST results were in 100% and 92.3% concordance with Sensititre DST results of clarithromycin (kappa coefficient, 1.0; 95% confidence interval [CI], 0.84 to 1.0) and amikacin (kappa coefficient, 0.752; 95% confidence interval [CI], 0.43 to 1.0). In addition, LRM-DST results for bedaquiline, moxifloxacin, imipenem, linezolid, and cefoxitin correlated well with Sensititre DST. Our findings suggest that LRM-DST can provide reliable phenotypic MAB-DST information in 48 h for prompt clinical management.IMPORTANCE&lt;i&gt;Mycobacterium abscessus&lt;/i&gt; (MAB) is a notorious human pathogen causing severe infections in individuals with cystic fibrosis and immunocompromised patients. Treatment options for MAB are very limited as they are resistant to multiple drugs through intrinsic and acquired resistance mechanisms. While macrolides and amikacin are the key drugs in the fight against MAB infections, emerging drug resistance is compromising their efficacy. Current growth-based drug susceptibility testing (DST) method takes 7 to 14 days to identify clarithromycin susceptibility due to the presence of inducible macrolide resistance and 3 to 5 days for other drugs. We developed a novel luciferase reporter mycobacteriophage (LRM) based phenotypic DST method using TM4::&lt;i&gt;GeNL&lt;/i&gt; to assess MAB drug susceptibility based on metabolic inhibition rather than growth. LRM-DST significantly reduces the DST turnaround time to 48 h and provides rapid assessment of MAB susceptibility to drugs, including inducible macrolide resistance, thereby accelerating the trea","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0084125"},"PeriodicalIF":5.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956133","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type-specific EV-D68 real-time RT-PCR assay for the detection of all extant enterovirus D68 strains.","authors":"Terry Fei Fan Ng, W Allan Nix, Shannon L Rogers, Brian Emery, Shur-Wern Chern, Kiantra Butler, M Steven Oberste","doi":"10.1128/jcm.01492-22","DOIUrl":"10.1128/jcm.01492-22","url":null,"abstract":"<p><p>We developed a type-specific Enterovirus D68 (EV-D68) real-time RT-PCR (rRT-PCR) assay termed CDC2022, which targets sequences encoding conserved amino acid regions of all extant EV-D68 strains. We targeted three motifs conserved among all strains in the last 60 years. The assay achieved 100% (281/281) sensitivity and 100% (344/344) specificity when tested with a collection of 625 respiratory specimens, compared to the gold-standard EV semi-nested VP1 PCR and sequencing assay (snPCR/Seq). CDC2022 gave negative results with 289/289 non-target viruses, including 104 EV A-D isolates, 165 rhinovirus (RV) isolates or clinical specimens, and 14 other common respiratory viruses. The limit of detection (LOD) of the CDC2022 assay is 361 copies per reaction, as determined using serially diluted RNA transcripts. It can detect as few as 0.28 CCID₅₀ per reaction with titrated isolates. An <i>in silico</i> \"phylo-primer-mismatch\" analysis was performed to visualize primer/probe mismatches and to compare CDC2022 with other EV-D68 rRT-PCR assays. It showed that CDC2022 has the fewest primer/probe mismatches among all assays analyzed and is suitable for all clades. As a type-specific assay targeting conserved amino acids, the CDC2022 assay allowed detection of newer strains from 2024. The CDC 2022 assay could provide a critical tool for molecular surveillance of EV-D68.IMPORTANCEEV-D68 has caused recurring respiratory disease outbreaks in the United States since 2014. As recurrent outbreaks and continued virus evolution are expected for EV-D68, the CDC2022 rRT-PCR provides a robust test that detects known strains as well as potential emerging strains. This type-specific assay approach is critical for national EV-D68 surveillance and clinical diagnostics. An <i>in silico</i> \"phylo-primer-mismatch\" approach is invented to show EV-D68 assay robustness, but it has utility in new molecular tests for pathogen detection.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0149222"},"PeriodicalIF":5.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421836/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"AveloMask, a novel breath aerosol collection kit for airborne <i>Mycobacterium tuberculosis</i>: a proof-of-principle assessment.","authors":"Patricia Risch, Tobias Broger, Zandile Booi, Katie Tiseo, Harshitha Santhosh Kumar, Jamie van Schalkwyk, Theresa Heinrich, Reto Willi, Stefan M Botha, Peter Sander, Adithya Cattamanchi, Stephan Hubold, Claudia M Denkinger, Grant Theron, Christina Fialová, Christian Adlhart, Rouxjeane Venter","doi":"10.1128/jcm.00546-25","DOIUrl":"10.1128/jcm.00546-25","url":null,"abstract":"<p><p>Tuberculosis (TB) remains the world's deadliest infectious disease, with many active cases missed due to challenges in sputum collection. Exhaled breath aerosols (XBA), a major route of <i>Mycobacterium tuberculosis</i> (MTB) transmission, offer a promising non-invasive alternative. This study evaluated the diagnostic accuracy and feasibility of the AveloMask-a novel point-of-care breath aerosol collection kit-for detecting active pulmonary TB using quantitative PCR (qPCR). In a pilot diagnostic accuracy study, 61 symptomatic, adult outpatients in Cape Town, South Africa, wore the mask for 45 min, coughing deeply at the start and end. XBAs were collected on integrated fiber filters transferred into stabilizing buffer via a simple push step and biobanked. XBA's were batch-analyzed by qPCR targeting the MTB-specific <i>IS6110</i> sequence. Diagnostic accuracy was assessed against sputum Xpert MTB/RIF Ultra (SXRS) and a composite microbiological reference standard (MRS), including culture. Of the 58 evaluable participants, 59% (34/58) had confirmed TB. Compared with SXRS, mask qPCR showed 71.0% (95% confidence interval [CI]: 53.4%-83.9%) sensitivity and 92.3% (95% CI:75.9%-97.9%) specificity. Against MRS, sensitivity was 64.7% (95% CI: 47.9%-78.5%) and specificity 91.7% (95% CI: 74.2%-97.7%). Sensitivity increased with bacterial load, reaching 100% in sputum with high MTB concentrations. MTB <i>IS6110</i> copy numbers in XBAs were low overall (175 copies [4-2,147]), likely due to insufficient DNA recovery or low aerosol bacilli. The mask sampling was well-tolerated by users. The AveloMask Kit shows promising diagnostic accuracy for TB and is feasible for point-of-care use. Further optimization and larger validation studies are warranted.IMPORTANCETuberculosis (TB) remains the world's deadliest infectious disease, yet diagnosis still relies heavily on sputum, which many patients struggle to produce. This study introduces the AveloMask Kit, a user-friendly, non-invasive face mask that captures exhaled aerosols and transfers them into a buffer tube for molecular detection of respiratory tract infections. In a clinical proof-of-principle study, AveloMask detected TB with promising accuracy and demonstrated feasibility in outpatient settings. By offering a non-invasive alternative to sputum, the AveloMask Kit addresses a critical diagnostic gap and could expand access to TB testing, particularly in resource-limited or primary care settings. Its simplicity enables use by minimally trained staff, and its stabilizing buffer allows ambient-temperature transport and biobanking, supporting broader case finding, safer sample collection, and future aerobiology research.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0054625"},"PeriodicalIF":5.4,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12421833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144955913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Standardized surveillance of blood culture contamination rates: moving toward a universal standard.","authors":"Fizza Manzoor, Sarah E Turbett","doi":"10.1128/jcm.00981-25","DOIUrl":"https://doi.org/10.1128/jcm.00981-25","url":null,"abstract":"<p><p>Blood culture contamination (BCC) is a major healthcare challenge with no standardized process to monitor and report rates by individual healthcare facilities in the United States. A new study by V. Fabre, Y.- J. Hsu, K. C. Caroll, A. M. Milstone, et al. (J Clin Microbiol 63:e0053025, 2025, https://doi.org/10.1128/jcm.00530-25) characterizes blood culture contamination rates, surveillance methods, reporting practices, and preventative strategies across 52 centers in the United States. The study highlights a need for standardized surveillance metrics and target thresholds within and across hospitals to help facilitate accurate benchmarking, provide feedback on existing processes, support antimicrobial and diagnostic stewardship efforts, and allocate resources to reduce BCC events.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0098125"},"PeriodicalIF":5.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Enhancing blood culture volume with ultrathin-wall cannula devices.","authors":"Grant Johnson, Valentin Parvu, Stephane Beauchamp, Mike Cuttler, Arek Zubrzycki, Lauren Cooper","doi":"10.1128/jcm.00208-25","DOIUrl":"https://doi.org/10.1128/jcm.00208-25","url":null,"abstract":"<p><p>Suboptimal blood volume collection negatively affects pathogen recovery and time to pathogen detection in clinical blood culture samples. This study evaluated the performance of the ultrathin-wall cannula device of the BD Vacutainer UltraTouch Push Button Blood Collection Set (UltraTouch; BD Life Sciences, Franklin Lakes, NJ) in increasing the blood volume collected compared to regular cannulas. In this retrospective study, the volume of blood collected in negative BD BACTEC Plus Aerobic/F Culture Vials prior to and following blind conversion to UltraTouch was measured from blood background metabolic activity signal acquired during the initial incubation period in the BD BACTEC FX instrument using a custom software application (patent pending). Differences in average fill volume between pre- and post-conversion were evaluated overall and by month. A separate logistic regression was also performed to model the relationship between monthly average blood volume increase (mL) and sample positivity rate. Prevalence rates for identified organisms were also assessed. The blood fill volume of 13,356 pre-conversion and 119,971 post-conversion bottles was compared. The average post-conversion fill volume was significantly higher than that of pre-conversion (7.56 mL [95% CI, 7.54-7.59] vs. 5.68 mL [95% CI, 5.62-5.74], respectively). This 1.88 mL increase in collected blood volume increased sample positivity from 7.0% to 7.7% (<i>P</i> = 0.002; odds ratio [OR], 1.11; 95% CI, 1.04-1.19). This study demonstrated that using an ultrathin-wall cannula blood collection device can significantly increase blood culture volume and sample positivity, supporting improved identification of patients suffering from bloodstream infections.IMPORTANCESubstandard blood fill volume practices in clinical settings negatively affect pathogen recovery which, in turn, may impact patients' care. Whereas professional education regarding the importance of adhering to clinical guidelines has been helpful in partly remediating the issue, the role of blood collection set technologies in optimizing blood culture volume has not been studied as thoroughly. Our study assessed the performance of the BD Vacutainer UltraTouch Push Button Blood Collection Set, which is designed with an ultrathin-wall cannula, to improve blood culture volume.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0020825"},"PeriodicalIF":5.4,"publicationDate":"2025-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145000593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging technologies for rapid phenotypic antimicrobial susceptibility testing of clinical isolates of bacteria.","authors":"Jacob Rattin, Malcolm Boswell, Daniel Rhoads","doi":"10.1128/jcm.00674-25","DOIUrl":"10.1128/jcm.00674-25","url":null,"abstract":"<p><p>Providing timely and accurate antimicrobial susceptibility testing (AST) results is a crucial component of clinical microbiology practice. Commercial rapid AST (RAST) is an emerging and quickly expanding area. These phenotypic RAST systems use various novel methods to monitor bacterial growth and replication in order to shorten the duration of time required for testing. Implementation of RAST has the potential to expedite antimicrobial therapeutic optimization, which can improve patient care. This minireview describes the current state of commercial phenotypic RAST including tests designed to report antimicrobial susceptibilities directly from clinical specimens.</p>","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0067425"},"PeriodicalIF":5.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a commercial multiplex pathogen panel for the diagnosis of pediatric <i>Kingella kingae</i> joint infections.","authors":"Philippe Bidet, Stéphane Bonacorsi, Matthis Lingua, Anne-Laure Simon, Marie Parizot, Marion Caseris, André Birgy","doi":"10.1128/jcm.01039-25","DOIUrl":"10.1128/jcm.01039-25","url":null,"abstract":"","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0103925"},"PeriodicalIF":5.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to \"Evaluation of a commercial multiplex pathogen panel for the diagnosis of pediatric <i>Kingella kingae</i> joint infections\".","authors":"Laura M Filkins, Lawson Copley","doi":"10.1128/jcm.01060-25","DOIUrl":"https://doi.org/10.1128/jcm.01060-25","url":null,"abstract":"","PeriodicalId":15511,"journal":{"name":"Journal of Clinical Microbiology","volume":" ","pages":"e0106025"},"PeriodicalIF":5.4,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144956090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}